This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
by Zacks Equity Research
HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.
HALOPositive Net Change RHHBYNegative Net Change JNJNegative Net Change ARGXPositive Net Change
biotechs earnings
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline
by Zacks Equity Research
Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.
SRPTNegative Net Change RHHBYNegative Net Change AMRXPositive Net Change IBRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
by Zacks Equity Research
Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.
HALOPositive Net Change
biotechs earnings
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
by Zacks Equity Research
Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
NVAXNegative Net Change SNYPositive Net Change PFEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
by Zacks Equity Research
Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.
IOVANegative Net Change MRKNegative Net Change TGTXPositive Net Change AMRXPositive Net Change
biotechs cell-therapy earnings immuno-therapy medical pharmaceuticals
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
by Zacks Equity Research
Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.
HRMYNegative Net Change TGTXPositive Net Change TAKNegative Net Change TARSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
DNLINegative Net Change BIIBNegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake
by Zacks Equity Research
Revolution Medicines' Q3 revenues beat estimates as Rasonque generated $197.6 million in just five weeks, signaling strong early launch demand.
RVMDNegative Net Change MRKNegative Net Change RPRXPositive Net Change ONCPositive Net Change
biotechs earnings medical pharmaceuticals
Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y
by Zacks Equity Research
VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.
VTRSPositive Net Change TGTXPositive Net Change AMRXPositive Net Change IBRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
by Zacks Equity Research
OCGN's Q3 revenues beat estimates. Shares surge 17.4%. Advancing gene therapy programs target three BLA submissions by 2028.
OCGNNegative Net Change TGTXPositive Net Change TARSPositive Net Change
biotechs earnings